The anti-VLA-4 antibody natalizumab induces erythroblastaemia in the majority of the treated patients with multiple sclerosis

Abstract

The presence of erythroblasts in the peripheral blood is generally associated with severe underlying disorders. The anti-very late antigen-4 (anti-VLA-4) antibody natalizumab, which is approved for treatment of multiple sclerosis, mediates an increase in circulating haematopoietic stem cells and may also trigger erythroblastaemia. We investigated the prevalence of erythroblastaemia in sequential blood smears of 14 natalizumab-treated and 14 interferon-treated patients with multiple sclerosis. Erythroblastaemia was found in 13 natalizumab-treated subjects (93%), whereas all controls were negative (p<0.0001). Knowledge of this frequent side effect is crucial for the correct interpretation of blood smears in natalizumab-treated patients and to avoid unnecessary diagnostic procedures.

Keywords

Erythroblastaemia erythroblasts natalizumab multiple sclerosis

Get full access to this article

View all access options for this article.

References

Tavassoli

. Erythroblastemia. West J Med 1975; 122: 194–198.

Polman

O’Connor

Havrdova

. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New Engl J Med 2006; 354: 899–910.

Ransohoff

. Natalizumab for multiple sclerosis. New Engl J Med 2007; 356: 2622–2629.

Hamamura

Matsuda

Takeuchi

. A critical role of VLA-4 in erythropoiesis in vivo. Blood 1996; 87: 2513–2517.

Bonig

Wundes

Chang

. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 2008; 111: 3439–3441.

Zohren

Toutzaris

Klärner

. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 2008; 111; 3893–3895.

Jing

Oelschlaegel

Ordemann

. CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function. Bone Marrow Transplant 2010; 45: 1489–1496.

Saure

Warnke

Zohren

. Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors. Arch Neurol 2011; 68: 1428–1431.

Papayannopoulou

Nakamoto

. Peripheralization of hemopoietic progenitors in primates treated with anti-VLA4 integrin. Proc Natl Acad Sci 1993; 90: 9374–9378.

10.

Rispens

Vennegoor

Wolbink

. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped. Mult Scler 2012; 18: 899–901.